Skip to content

Study · Systematic review · n = 13,330 · 2023

7 results

Semaglutide and cancer: A systematic review and meta-analysis.

Nagendra L, Bg H, Sharma M, Dutta D

Diabetes & metabolic syndrome26 Jul 2023Cited by 68 (Europe PMC)

PMID37531876 (opens in a new tab)DOI10.1016/j.dsx.2023.102834 (opens in a new tab)PepBankPUB-37531876
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials, pancreatic cancer occurrence was similar with semaglutide and placebo.

    In plain wordsIn pooled trials, pancreatic cancer occurred about as often with semaglutide as with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreatic cancer vs placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    OR
    0.25 ratio
    pancreatic cancer vs placebo

    Source sentences

    Summary
    pancreatic cancer [OR 0.25 (95%CI: 0.03-2.24); P = 0.21]
    1 context sentence
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials, thyroid cancer occurrence was similar with semaglutide and placebo.

    In plain wordsIn pooled trials, thyroid cancer occurred about as often with semaglutide as with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeThyroid cancer vs placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    OR
    2.04 ratio
    thyroid cancer vs placebo

    Source sentences

    Summary
    thyroid cancer [OR 2.04 (95%CI: 0.33-12.61); P = 0.44
    1 context sentence
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials, pancreatic cancer occurrence was similar with semaglutide and active controls.

    In plain wordsIn pooled trials, pancreatic cancer occurred about as often with semaglutide as with other active drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changePancreatic cancer vs active controls
    Study

    n: not reported in source

    Comparator
    Active controls
    Analysis
    Primary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    OR
    0.4 ratio
    pancreatic cancer vs active controls

    Source sentences

    Summary
    pancreatic cancer [OR 0.40 (95%CI:0.09-1.87); P = 0.26
    1 context sentence
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.
  4. 04HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials, thyroid cancer occurrence was similar with semaglutide and active controls.

    In plain wordsIn pooled trials, thyroid cancer occurred about as often with semaglutide as with other active drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeThyroid cancer vs active controls
    Study

    n: not reported in source

    Comparator
    Active controls
    Analysis
    Primary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    OR
    1.19 ratio
    thyroid cancer vs active controls

    Source sentences

    Summary
    thyroid cancer [OR 1.19 (95%CI:0.15-9.66); P = 0.87
    1 context sentence
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.
  5. 05HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials, occurrence of all neoplasms was similar with semaglutide and placebo.

    In plain wordsIn pooled trials, tumours of any kind occurred about as often with semaglutide as with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeAll neoplasms vs placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    OR
    0.95 ratio
    all neoplasms vs placebo

    Source sentences

    Summary
    all neoplasms (benign, malignant and otherwise unspecified) [OR 0.95 (95%CI:0.62-1.45); P = 0.82; I2 = 0%] was similar in the semaglutide group.
    1 context sentence
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.
  6. 06HumanSystematic reviewSafety outcome

    In a meta-analysis of semaglutide trials, occurrence of all neoplasms was similar with semaglutide and active controls.

    In plain wordsIn pooled trials, tumours of any kind occurred about as often with semaglutide as with other active drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeAll neoplasms vs active controls
    Study

    n: not reported in source

    Comparator
    Active controls
    Analysis
    Secondary
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    OR
    0.91 ratio
    all neoplasms vs active controls

    Source sentences

    Summary
    all neoplasms (benign, malignant and otherwise unspecified) [OR 0.91 (95% CI: 0.44-1.89); P = 0.79; I2 = 0%] were similar in the semaglutide group.
    1 context sentence
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.
  7. 07HumanSystematic reviewSafety outcome

    In real-world studies of semaglutide, data analysis found a single case each of pancreatic cancer and B-cell lymphoma.

    In plain wordsIn real-world studies of people taking semaglutide, one case of pancreatic cancer and one case of B-cell lymphoma were found.

    Peptide
    Semaglutide
    Outcome
    Not applicableCancers in real-world studies
    Study

    n = 13,330

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Real-world data analysis revealed single case each of pancreatic cancer and B-cell lymphoma.
    2 context sentences
    Summary · context
    Data from 37 RCTs and 19 real-world studies having 16,839 patients in placebo-control group, 16,550 patients in active-control group and 13,330 patients in real-world studies were analysed.
    Summary · context
    Databases were searched for randomized controlled trials (RCTs) and real-world studies involving patients receiving semaglutide in the intervention-arm.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.